Cargando…

Type 1 diabetes and COVID-19: The “lockdown effect”

AIMS: The aim of this study was to evaluate the effect the lockdown imposed during COVID-19 outbreak on the glycemic control of people with Type 1 diabetes (T1D) using Continuous (CGM) or Flash Glucose Monitoring (FGM). MATERIALS AND METHODS: We retrospectively analyzed glucose reading obtained by F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aragona, Michele, Rodia, Cosimo, Bertolotto, Alessandra, Campi, Fabrizio, Coppelli, Alberto, Giannarelli, Rosa, Bianchi, Cristina, Dardano, Angela, Del Prato, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518840/ https://www.ncbi.nlm.nih.gov/pubmed/32987040 http://dx.doi.org/10.1016/j.diabres.2020.108468

Ejemplares similares

Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy
por: Falcetta, Pierpaolo, et al.
Publicado: (2021)

Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies
por: Garofolo, Monia, et al.
Publicado: (2021)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
por: Dardano, Angela, et al.
Publicado: (2022)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Insulin as an Early Treatment for Type 2 Diabetes: ORIGIN or end of an old question?
por: Del Prato, Stefano, et al.
Publicado: (2013)

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
por: Garofolo, Monia, et al.
Publicado: (2019)

Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
por: Garofolo, Monia, et al.
Publicado: (2021)

COVID-19 in people with diabetes: understanding the reasons for worse outcomes
por: Apicella, Matteo, et al.
Publicado: (2020)

Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
por: Dardano, Angela, et al.
Publicado: (2021)

Optimal therapy of type 2 diabetes: a controversial challenge
por: Dardano, Angela, et al.
Publicado: (2014)

Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study
por: Garofolo, Monia, et al.
Publicado: (2020)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
por: Dardano, Angela, et al.
Publicado: (2021)

SIRT1 rs7896005 polymorphism affects major vascular outcomes, not all‐cause mortality, in Caucasians with type 2 diabetes: A 13‐year observational study
por: Dardano, Angela, et al.
Publicado: (2022)

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
por: Sancho, Veronica, et al.
Publicado: (2017)

Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge
por: Dardano, Angela, et al.
Publicado: (2020)

Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
por: Daniele, Giuseppe, et al.
Publicado: (2020)

Altered Visual Plasticity in Morbidly Obese Subjects
por: Lunghi, Claudia, et al.
Publicado: (2019)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Incretins and cardiovascular disease: to the heart of type 2 diabetes?
por: Solini, Anna, et al.
Publicado: (2023)

Effect of fasting on short‐term visual plasticity in adult humans
por: Animali, Silvia, et al.
Publicado: (2022)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women
por: Ghio, Alessandra, et al.
Publicado: (2012)

Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete
por: Apicella, Matteo, et al.
Publicado: (2020)

Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Outcome studies versus clinical experience in the treatment of diabetes
por: Raz, Itamar, et al.
Publicado: (2011)

The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
por: Vaccaro, Olga, et al.
Publicado: (2012)

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Quantitative assessment of early biomechanical modifications in diabetic foot patients: the role of foot kinematics and step width
por: Lamola, Giuseppe, et al.
Publicado: (2015)

Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
por: Del Prato, Stefano, et al.
Publicado: (2013)

Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
por: Prato, S Del, et al.
Publicado: (2010)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Effects of Intermittent Fasting on Brain Metabolism
por: Brocchi, Alex, et al.
Publicado: (2022)

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Has COVID-19 lockdown improved glycaemic control in pediatric patients with type 1 diabetes? An analysis of continuous glucose monitoring metrics
por: Lombardo, Fortunato, et al.
Publicado: (2021)

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown
por: Ciprandi, Riccardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7gu34nv9kbngvtsuq07ns6v1dv